Connect
← Return to Clinical Trials: they are not designed only to be a “last resort”
Discussion
Clinical Trials: they are not designed only to be a “last resort”
Pancreatic Cancer | Last Active: Sep 13 7:47am | Replies (42)Comment receiving replies
You're a weath of information, sir. I'm feeling more assured that if I'm still here in June of '26, the end of my NIH trial, I'll be able to continue using the Olaparib. And if anyone reading this forum has pancreatic acinar cell cancer, and also has the BRCA2 mutation, the clinical trial I'm in is still looking for participants. They are looking for 20 patients but so far I'm the only one in the trial. The NIH protocol title for the trial is "000596-C: Phase II study of Olaparib in subjects with advanced Pancreatic Acinar Cell Carcinoma". The contact doctor is Christine Alewine. I don't have her ph. no. handy. I was concerned that, since this study is government funded, they might pull the plug on it due to lack of participants. Dr. Alewine said, "That's not going to happen." I'm hoping some others come forward.
Replies to "You're a weath of information, sir. I'm feeling more assured that if I'm still here in..."
Connect
I’m in the Natural History study of Dr. Alawine. I’ve talked to one of the M.D.’s in her group and a couple of nurses and they have been reviewing the medical records of my case history for the factors that may have led to the longevity and being considered an “exceptional responder” that resulted in cure. At some point in the future I will heading down to the NIH campus.
The concern in pulling the plug on a study is not the funding as that was already allocated for the study by the NCI. What results in a trial being terminated is failure to accrue the pre-determined number of participants necessary to obtain enough statistical data to make valid conclusions.